EUROPEAN: bourses were all significantly stronger in the reporting period to August 11, having put in a poor showing the previous week, being helped by lower crude oil prices. Leading European pharmaceutical companies outperformed their national market indexes ahead of the weekend, but flattened on the final day. PARIS saw a strong 6.9% advance for Sanofi-Aventis, which had dipped the week earlier on disappointing second-quarter results, with a similar reaction for UCB in BRUSSELS, where the firm was up 15% despite posting a 37% first-half profits fall (Marketletter August 11). ZURICH witnessed a 3.9% downturn in drug major Roche, which is bidding for control of majority-owned, USA-based Genentech (Marketletter July 28) and is expected to increase its offer price of $89 a share significantly. Fellow Swiss major Novartis was also down, falling 1.9% on the week, but levelling off from its 3.1% fall on August 6, after a downgrade from analysts at JP Morgan. Crucell was strong ahead of results, rising 9.8% on the AMSTERDAM bourse over the reported week
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.
Stock Commentary - Europe - week to Aug 11, 2008
EUROPEAN: bourses were all significantly stronger in the reporting period to August 11, having put in a poor showing the previous week, being helped by lower crude oil prices. Leading European pharmaceutical companies outperformed their national market indexes ahead of the weekend, but flattened on the final day. PARIS saw a strong 6.9% advance for Sanofi-Aventis, which had dipped the week earlier on disappointing second-quarter results, with a similar reaction for UCB in BRUSSELS, where the firm was up 15% despite posting a 37% first-half profits fall (Marketletter August 11). ZURICH witnessed a 3.9% downturn in drug major Roche, which is bidding for control of majority-owned, USA-based Genentech (Marketletter July 28) and is expected to increase its offer price of $89 a share significantly. Fellow Swiss major Novartis was also down, falling 1.9% on the week, but levelling off from its 3.1% fall on August 6, after a downgrade from analysts at JP Morgan. Crucell was strong ahead of results, rising 9.8% on the AMSTERDAM bourse over the reported week
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Company News Directory
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
| Headless Content Management with Blaze